Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 22 | 2026 | 1459 | 6.400 |
Why?
|
| Community Health Workers | 7 | 2026 | 87 | 3.890 |
Why?
|
| Telemedicine | 8 | 2026 | 526 | 3.490 |
Why?
|
| Hypoglycemic Agents | 8 | 2026 | 480 | 2.950 |
Why?
|
| Diabetes Mellitus | 7 | 2025 | 889 | 2.170 |
Why?
|
| Cardiovascular Diseases | 14 | 2026 | 2121 | 1.470 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2025 | 33 | 0.910 |
Why?
|
| Patient Education as Topic | 2 | 2026 | 464 | 0.850 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2025 | 512 | 0.770 |
Why?
|
| Metformin | 3 | 2024 | 174 | 0.770 |
Why?
|
| Self-Management | 1 | 2024 | 120 | 0.740 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2025 | 280 | 0.710 |
Why?
|
| Poverty | 5 | 2025 | 462 | 0.680 |
Why?
|
| Diabetic Foot | 1 | 2022 | 172 | 0.610 |
Why?
|
| Patient Selection | 1 | 2023 | 729 | 0.610 |
Why?
|
| Humans | 47 | 2026 | 131163 | 0.580 |
Why?
|
| House Calls | 1 | 2019 | 35 | 0.570 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 146 | 0.560 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 86 | 0.550 |
Why?
|
| Psychotherapy, Group | 1 | 2017 | 58 | 0.510 |
Why?
|
| Cardiology | 5 | 2025 | 514 | 0.500 |
Why?
|
| Veterans | 3 | 2022 | 1763 | 0.480 |
Why?
|
| Adult | 14 | 2026 | 31282 | 0.480 |
Why?
|
| Middle Aged | 13 | 2026 | 28601 | 0.430 |
Why?
|
| Drug Therapy, Combination | 3 | 2026 | 1173 | 0.410 |
Why?
|
| Patient Care Team | 1 | 2017 | 562 | 0.390 |
Why?
|
| Breast Neoplasms | 1 | 2025 | 2602 | 0.380 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 919 | 0.370 |
Why?
|
| Sulfonylurea Compounds | 2 | 2024 | 20 | 0.360 |
Why?
|
| Aged | 10 | 2025 | 21025 | 0.360 |
Why?
|
| Thiazolidinediones | 2 | 2024 | 81 | 0.350 |
Why?
|
| Female | 17 | 2026 | 70963 | 0.320 |
Why?
|
| Male | 16 | 2026 | 64957 | 0.300 |
Why?
|
| Quality of Life | 4 | 2024 | 2082 | 0.270 |
Why?
|
| Social Work | 1 | 2026 | 22 | 0.240 |
Why?
|
| Global Health | 3 | 2026 | 626 | 0.240 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2023 | 744 | 0.240 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2025 | 44 | 0.230 |
Why?
|
| Medicine | 1 | 2026 | 101 | 0.220 |
Why?
|
| Texas | 2 | 2026 | 3686 | 0.210 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 30 | 0.200 |
Why?
|
| Obesity | 4 | 2025 | 2426 | 0.200 |
Why?
|
| Community Health Centers | 1 | 2023 | 35 | 0.200 |
Why?
|
| Primary Prevention | 1 | 2024 | 183 | 0.190 |
Why?
|
| Feedback | 1 | 2023 | 144 | 0.190 |
Why?
|
| Depression | 2 | 2023 | 1320 | 0.190 |
Why?
|
| Publishing | 1 | 2024 | 105 | 0.180 |
Why?
|
| Parenting | 1 | 2026 | 348 | 0.180 |
Why?
|
| Primary Health Care | 2 | 2026 | 775 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1267 | 0.180 |
Why?
|
| Health Education | 1 | 2024 | 228 | 0.180 |
Why?
|
| Patient Satisfaction | 1 | 2025 | 464 | 0.170 |
Why?
|
| Research Design | 2 | 2023 | 716 | 0.170 |
Why?
|
| Pediatric Obesity | 2 | 2017 | 419 | 0.170 |
Why?
|
| Anticholesteremic Agents | 1 | 2023 | 239 | 0.170 |
Why?
|
| Social Support | 1 | 2023 | 370 | 0.170 |
Why?
|
| Rural Population | 1 | 2023 | 276 | 0.170 |
Why?
|
| Sleep Wake Disorders | 1 | 2023 | 204 | 0.160 |
Why?
|
| Risk Factors | 6 | 2026 | 11074 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2026 | 523 | 0.160 |
Why?
|
| Lower Extremity | 1 | 2022 | 185 | 0.160 |
Why?
|
| Multimorbidity | 1 | 2020 | 23 | 0.160 |
Why?
|
| Goals | 1 | 2021 | 126 | 0.160 |
Why?
|
| Health Status Indicators | 1 | 2020 | 111 | 0.150 |
Why?
|
| Insulins | 1 | 2020 | 18 | 0.150 |
Why?
|
| Weight Reduction Programs | 1 | 2020 | 59 | 0.150 |
Why?
|
| Mentors | 1 | 2021 | 170 | 0.150 |
Why?
|
| Congresses as Topic | 3 | 2025 | 184 | 0.150 |
Why?
|
| Videoconferencing | 1 | 2019 | 21 | 0.150 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 6797 | 0.140 |
Why?
|
| Telephone | 1 | 2019 | 111 | 0.140 |
Why?
|
| Group Processes | 1 | 2019 | 48 | 0.140 |
Why?
|
| Parents | 1 | 2026 | 1128 | 0.140 |
Why?
|
| Medicaid | 1 | 2021 | 268 | 0.140 |
Why?
|
| Behavior Therapy | 1 | 2021 | 273 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2019 | 351 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2019 | 197 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2025 | 12936 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2020 | 297 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2020 | 711 | 0.130 |
Why?
|
| Body Mass Index | 3 | 2020 | 1717 | 0.130 |
Why?
|
| Life Style | 4 | 2021 | 456 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2021 | 1445 | 0.130 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2023 | 642 | 0.120 |
Why?
|
| Anxiety | 1 | 2023 | 1014 | 0.120 |
Why?
|
| United States | 7 | 2026 | 12072 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2017 | 761 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2026 | 1223 | 0.120 |
Why?
|
| Seasons | 1 | 2017 | 335 | 0.120 |
Why?
|
| Weight Loss | 4 | 2021 | 538 | 0.120 |
Why?
|
| Child Behavior | 1 | 2017 | 232 | 0.120 |
Why?
|
| Blood Pressure | 1 | 2021 | 1345 | 0.110 |
Why?
|
| Acculturation | 1 | 2015 | 62 | 0.110 |
Why?
|
| Body Weight | 2 | 2017 | 987 | 0.110 |
Why?
|
| Pandemics | 1 | 2022 | 1118 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2017 | 824 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1378 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2019 | 1117 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2023 | 5063 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2022 | 948 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 712 | 0.100 |
Why?
|
| Young Adult | 2 | 2025 | 10103 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2025 | 17753 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 5196 | 0.090 |
Why?
|
| Overweight | 3 | 2021 | 387 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 4066 | 0.080 |
Why?
|
| Global Burden of Disease | 1 | 2026 | 37 | 0.060 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2023 | 7 | 0.050 |
Why?
|
| Kenya | 1 | 2023 | 60 | 0.050 |
Why?
|
| Europe | 1 | 2024 | 365 | 0.050 |
Why?
|
| Editorial Policies | 1 | 2024 | 49 | 0.050 |
Why?
|
| Writing | 1 | 2024 | 59 | 0.050 |
Why?
|
| Proprotein Convertase 9 | 1 | 2023 | 108 | 0.050 |
Why?
|
| Exercise | 2 | 2020 | 892 | 0.050 |
Why?
|
| American Heart Association | 1 | 2025 | 343 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2025 | 295 | 0.050 |
Why?
|
| Data Collection | 1 | 2023 | 370 | 0.040 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 77 | 0.040 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 51 | 0.040 |
Why?
|
| Cardiotonic Agents | 1 | 2022 | 138 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 798 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 604 | 0.040 |
Why?
|
| Diet, Reducing | 1 | 2020 | 92 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2023 | 282 | 0.040 |
Why?
|
| Caloric Restriction | 1 | 2020 | 107 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1490 | 0.040 |
Why?
|
| Prevalence | 1 | 2026 | 2701 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 369 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2021 | 338 | 0.030 |
Why?
|
| Glucose | 1 | 2022 | 853 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2017 | 169 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1246 | 0.030 |
Why?
|
| Pregnancy | 1 | 2026 | 7512 | 0.020 |
Why?
|
| Child | 2 | 2017 | 26341 | 0.010 |
Why?
|
| Adolescent | 1 | 2023 | 20987 | 0.010 |
Why?
|